Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

14.5K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
14.5K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

15.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
15.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical efficacy and safety of pembrolizumab and nivolumab in frontline treatment for classical Hodgkin lymphoma: systematic review and meta-analysis of clinical trials.

Frontiers in oncology·2026
Same author

Longitudinal plasma neurofilament light chain and patient-reported outcomes as complementary markers of vincristine-associated peripheral neuropathy in adults with lymphoma: a cohort study.

medRxiv : the preprint server for health sciences·2026
Same author

Opportunities to enhance cancer research through advocate-researcher partnerships.

Cancer research·2026
Same author

Tocilizumab as stabilizing frontline treatment in suspected KSHV inflammatory cytokine syndrome.

Blood advances·2026
Same author

Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease.

Blood neoplasia·2026
Same author

Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexate.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

Related Experiment Video

Updated: Jan 10, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.0K

EBV-Positive Diffuse Large B-Cell Lymphoma (DLBCL): An Assessment and a Roadmap.

Pierluigi Porcu1, Rebecca Masel2, Nicholas Kendsersky3

  • 1Division of Hematology and BMT, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.

Journal of Medical Virology
|November 27, 2025
PubMed
Summary

Epstein-Barr Virus (EBV) is found in 5-15% of Diffuse Large B-cell Lymphoma (DLBCL) cases. EBV-positive DLBCL has unique features and EBV is a prognostic biomarker, with ongoing research into targeted therapies.

Keywords:
DLBCLEBVglobalimmunocompetentimmunocompromisedimmunotherapylatencylyticmicroenvironment

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.2K
Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

41.2K

Related Experiment Videos

Last Updated: Jan 10, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.0K
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.2K
Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

41.2K

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Diffuse Large B-cell Lymphoma (DLBCL) is the most common lymphoma globally.
  • Epstein-Barr Virus (EBV) is linked to various human cancers.
  • EBV DNA is present in 5-15% of DLBCL tumors in immunocompetent individuals.

Purpose of the Study:

  • To review current clinical and molecular data on EBV-positive DLBCL.
  • To discuss novel therapeutic strategies targeting EBV in DLBCL.
  • To identify key unanswered questions in EBV-positive DLBCL research.

Main Methods:

  • Literature review of recent clinical and molecular studies on EBV-positive DLBCL.
  • Analysis of the impact of modern chemo-immunotherapy on EBV-positive DLBCL.
  • Exploration of the distinct mutational landscape and immune microenvironment.

Main Results:

  • EBV-positive DLBCL exhibits distinct clinical features, tumor microenvironment (TME), and historically, poorer survival.
  • Modern treatments have refined the understanding and outcomes of EBV-positive DLBCL.
  • EBV is confirmed as an independent prognostic biomarker in DLBCL.

Conclusions:

  • EBV-positive DLBCL is a distinct clinicopathological entity.
  • Further research is crucial for developing targeted EBV therapies.
  • Understanding EBV's role is key to improving DLBCL patient outcomes.